NCT07296575 2025-12-22
Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration
Second Affiliated Hospital of Nanchang University
Active not recruiting
Clinical Trials
19 trialsNCT03109847 2025-12-11
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
Thomas Jefferson University
Phase 2 Terminated
NCT07239674 2025-11-20
DELTA
West China Hospital
Phase 3 Not yet recruiting
NCT00673010 2025-10-09
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04623801 2025-10-08
Laser Ablation of Papillary Thyroid Microcarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02776969 2025-10-03
A Gene Hunting Study for Familial Papillary Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Active not recruiting
NCT05774535 2025-10-02
TIROVASC
Istituto Auxologico Italiano
Withdrawn
NCT06455371 2025-09-10
Patient-centered Dosage of Levothyroxine
University Hospital of North Norway
Phase NA Recruiting
NCT06868459 2025-09-08
Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry
Sarasota Memorial Health Care System
Enrolling by invitation
NCT05660954 2025-09-05
CABOTHYROID
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Active not recruiting
NCT05579782 2025-07-31
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy
Medical College of Wisconsin
Phase NA Completed
NCT06054178 2025-07-28
Identification of Nerves Using Fluorescein Sodium
Stanford University
Phase 2 Enrolling by invitation
NCT01141309 2025-07-22
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07064369 2025-07-14
OTELLO
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrolling by invitation
NCT05059470 2025-07-08
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02747888 2025-05-19
Hereditary Risk Factors for Thyroid Cancer
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT05733013 2025-04-24
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Recruiting
NCT06752239 2025-04-10
PROTECT-NPC
Jiangxi Provincial Cancer Hospital
Phase 3 Recruiting
NCT06901908 2025-04-03
Role of Cytomorphometry and BRAFV600E Immunocytochemistry With a Cytologic Diagnosis "Suspicious for Papillary Thyroid Carcinoma"
Assiut University
Not yet recruiting